DanCann Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of DANCAN?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	5,209,211	0.338%
Institutions	130,899,484	8.49%
General Public	1,404,987,655	91.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 988.1%.

Top Shareholders

Top 8 shareholders own 8.83% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
6.81%	Avanza Fonder AB	104,876,936	DKK 251.7k	0%	no data
1.69%	Nordic Growth Oy	26,022,548	DKK 62.5k	0%	no data
0.23%	Jeppe Rasmussen	3,500,000	DKK 8.4k	0%	no data
0.054%	Tue Ostergaard	833,340	DKK 2.0k	0%	no data
0.027%	Carsten Trads	409,031	DKK 981.6	0%	no data
0.016%	Christian Carlsen	241,834	DKK 580.3	0%	no data
0.013%	Louise Conradsen	200,004	DKK 480.1	0%	no data
0.0016%	Sarah Lykke-Kjeldsen	25,002	DKK 59.9	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 12:09
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DanCann Pharma A/S is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Markus Augustsson	Carlsquare AB
Jonatan Andersson	Carlsquare AB
Fredrik Nilsson	Carlsquare AB